As a Master of Health Administration (MHA) candidate at the University of Miami and a Program […]
The costs associated with missed milestones and timeline extensions are significant and can derail the trial entirely. Less than 10% of drug candidates reach approval, with sponsors often incurring the costs associated with failed clinical trials, or trials that are behind schedule. Playing the “blame-game” while a clinical trial fails will only slow down the rescue process and increase these costs. It is paramount that sponsors and CROs are proactively monitoring trial progress and working together to address issues as they arise.